These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30723467)

  • 1. Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA.
    Boscheinen JB; Thomann S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Dörrie J; Schaft N; Bach C; Rohrhofer A; Werner-Klein M; Schmidt B; Schuster P
    Front Immunol; 2019; 10():2. PubMed ID: 30723467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1.
    Lindner G; Walter A; Magnus CL; Rosenhammer K; Holoborodko B; Koch V; Hirsch S; Grossmann L; Li S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Schwertner B; Toelge M; Rohrhofer A; Stöckl S; Bauer RJ; Knoll G; Ehrenschwender M; Haferkamp S; Schmidt B; Schuster P
    Immunology; 2024 Jun; 172(2):279-294. PubMed ID: 38444199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.
    Workenhe ST; Simmons G; Pol JG; Lichty BD; Halford WP; Mossman KL
    Mol Ther; 2014 Jan; 22(1):123-31. PubMed ID: 24343053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiating Oncolytic Virus-Induced Immune-Mediated Tumor Cell Killing Using Histone Deacetylase Inhibition.
    Jennings VA; Scott GB; Rose AMS; Scott KJ; Migneco G; Keller B; Reilly K; Donnelly O; Peach H; Dewar D; Harrington KJ; Pandha H; Samson A; Vile RG; Melcher AA; Errington-Mais F
    Mol Ther; 2019 Jun; 27(6):1139-1152. PubMed ID: 31053413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncognate Signals Drive Enhanced Effector CD8
    Gmyrek GB; Predki P; Gershburg E; Carr DJJ
    J Virol; 2022 Mar; 96(6):e0172421. PubMed ID: 35045268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice.
    Thomas ED; Meza-Perez S; Bevis KS; Randall TD; Gillespie GY; Langford C; Alvarez RD
    J Ovarian Res; 2016 Oct; 9(1):70. PubMed ID: 27784340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Virus Therapy with HSV-1 for Hematological Malignancies.
    Ishino R; Kawase Y; Kitawaki T; Sugimoto N; Oku M; Uchida S; Imataki O; Matsuoka A; Taoka T; Kawakami K; van Kuppevelt TH; Todo T; Takaori-Kondo A; Kadowaki N
    Mol Ther; 2021 Feb; 29(2):762-774. PubMed ID: 33038943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells.
    Thomann S; Boscheinen JB; Vogel K; Knipe DM; DeLuca N; Gross S; Schuler-Thurner B; Schuster P; Schmidt B
    Immunology; 2015 Oct; 146(2):327-38. PubMed ID: 26194553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
    Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N
    Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
    Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
    Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved antitumor effects elicited by an oncolytic HSV-1 expressing a novel B7H3nb/CD3 BsAb.
    Zhang Z; Yang N; Lu H; Chen Y; Xu L; Wang Z; Lu Q; Zhong K; Zhu Z; Wang G; Li H; Zheng M; Zhang W; Yang H; Peng X; Zhou L; Tong A
    Cancer Lett; 2024 Apr; 588():216760. PubMed ID: 38428724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human Asymptomatic Epitopes Identified from the Herpes Simplex Virus Tegument Protein VP13/14 (UL47) Preferentially Recall Polyfunctional Effector Memory CD44high CD62Llow CD8+ TEM Cells and Protect Humanized HLA-A*02:01 Transgenic Mice against Ocular Herpesvirus Infection.
    Srivastava R; Khan AA; Garg S; Syed SA; Furness JN; Vahed H; Pham T; Yu HT; Nesburn AB; BenMohamed L
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27847359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients.
    Tuettenberg A; Becker C; Huter E; Knop J; Enk AH; Jonuleit H
    Int J Cancer; 2006 May; 118(10):2617-27. PubMed ID: 16353138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and validation of recombinant herpes simplex type 1 viruses (HSV-1) using CRISPR/Cas9 genetic disruption.
    Bommareddy PK; Peters C; Kaufman HL
    Methods Enzymol; 2020; 635():167-184. PubMed ID: 32122544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Oncolytic Herpes Simplex Virus 1 VC2 Promotes Long-Lasting, Systemic Anti-melanoma Tumor Immune Responses and Increased Survival in an Immunocompetent B16F10-Derived Mouse Melanoma Model.
    Uche IK; Fowlkes N; Vu L; Watanabe T; Carossino M; Nabi R; Del Piero F; Rudd JS; Kousoulas KG; Rider PJF
    J Virol; 2021 Jan; 95(3):. PubMed ID: 33177208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of Oncolytic Herpes Simplex Virus with Therapeutic Genes of Interest.
    Kahramanian A; Kuroda T; Wakimoto H
    Methods Mol Biol; 2019; 1937():177-188. PubMed ID: 30706396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficient Strategy for Synthesizing Vector-Free and Oncolytic Herpes Simplex Type 1 Viruses.
    Xiao H; Hu H; Guo Y; Li J; Zeng WB; Luo MH; Wang M; Hu Z
    ACS Synth Biol; 2024 Oct; 13(10):3268-3280. PubMed ID: 39358309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular engineering and validation of an oncolytic herpes simplex virus type 1 transcriptionally targeted to midkine-positive tumors.
    Maldonado AR; Klanke C; Jegga AG; Aronow BJ; Mahller YY; Cripe TP; Crombleholme TM
    J Gene Med; 2010 Jul; 12(7):613-23. PubMed ID: 20603890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
    Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
    EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.